BiotechTube

Esomeprazole + Aspirin + Rofecoxib

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Barrett's Esophagus

Conditions

Barrett's Esophagus

Trial Timeline

Apr 1, 2002 → Jun 1, 2003

NCT ID
NCT00637988

About Esomeprazole + Aspirin + Rofecoxib

Esomeprazole + Aspirin + Rofecoxib is a approved stage product being developed by AstraZeneca for Barrett's Esophagus. The current trial status is completed. This product is registered under clinical trial identifier NCT00637988. Target conditions include Barrett's Esophagus.

What happened to similar drugs?

2 of 2 similar drugs in Barrett's Esophagus were approved

Approved (2) Terminated (0) Active (0)
✅Esomeprazole + LansoprazoleAstraZenecaApproved
✅Esomeprazole MagnesiumAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00637988ApprovedCompleted

Competing Products

3 competing products in Barrett's Esophagus

See all competitors
ProductCompanyStageHype Score
Esomeprazole + LansoprazoleAstraZenecaApproved
43
Esomeprazole MagnesiumAstraZenecaApproved
43
ChemotherapyPacific BiosciencesPre-clinical
23